WebAn Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies Latest version (submitted June 29, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. WebHistone Demethylase compound (inhibitors, antagonists, inducers) with high quality and purity, chemical tool in various assays for drug discovery and biological epigenetics research, potent, selective LSD1, KDM, JmjC demethylase small molecule inhibitor.
INCB059872 LSD1 Inhibitor MedChemExpress
WebApr 20, 2024 · Drug: INCB059872 Study Type Interventional Enrollment (Actual) 25 Phase Phase 1 Contacts and Locations This section provides the contact details for those conducting the study, and information on where this study is being conducted. Study Locations Italy Bologna, Italy, 40136 Istituto Ortopedico Rizzoli Bologna, Italy, 40138 WebINCB059872, INCB59872 - Product Profiles - BCIQ For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. green berry signature lucknow
INCB059872 S530576 >98% (or refer to the COA) smolecule
WebDec 4, 2024 · Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 … WebApr 14, 2016 · Prot #INCB 59872-101: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced … WebLARVOL VERI predictive biomarker analytics, INCB59872. Full access to predictive biomarker details and heatmap analytics are available with a VERI Account. flowers northern beaches sydney delivery